EPO published Merus B.V.'s patent application EP3757129A1 for a human CD3 binding antibody (C07K 16/28) with therapeutic applications in cancer treatment (A61P 35/00, A61P 35/02). The patent names inventors Bakker and van Loo, with IPC classifications indicating antibody therapeutics and medicinal preparations. Designated states include all major European markets (DE, FR, GB, IT, ES, NL, BE, CH, etc.).

Pharmaceutical companies developing competing CD3-targeted antibodies should review the claims for potential freedom-to-operate concerns. Research institutions and biotech firms conducting similar work should assess whether their technologies may infringe the published claims. The publication establishes priority dates from October 2020, which may affect earlier patent filings by competitors.